Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis

Overview

Journal Arthritis Care Res (Hoboken)

Specialty Rheumatology

Date 2016 Jun 9

PMID 27273801

Citations 16

Authors

Brian C Sauer

Chia-Chen Teng

Derek Tang

Jianwei Leng

Jeffrey R Curtis

Ted R Mikuls

David J Harrison

Grant W Cannon

Affiliations

Soon will be listed here.

Abstract

Objective: To compare persistence and adherence to triple therapy with the nonbiologic disease-modifying antirheumatic drugs (DMARDs) methotrexate (MTX), hydroxychloroquine, and sulfasalazine, versus a tumor necrosis factor inhibitor (TNFi) plus MTX in patients with rheumatoid arthritis (RA).

Methods: Administrative and laboratory data were analyzed for US Veterans with RA initiating triple therapy or TNFi + MTX between January 2006 and December 2012. Treatment persistence 365 days postindex was calculated using 3 definitions. Definition 1 required no gap in therapy of ≥90 days for any drug in the original combination. Definition 2 required no added or switched DMARD, no decrease to nonbiologic DMARD monotherapy, and no termination of all DMARD therapies. Definition 3 was similar to definition 2 but allowed a switch to another drug within the same class. Adherence used a proportion of days covered of ≥80%. Propensity-weighted analysis with matched weights was used to balance covariates.

Results: The analysis included 4,364 RA patients (TNFi + MTX, n = 3,204; triple therapy, n = 1,160). In propensity-weighted analysis, patients in the TNFi + MTX group were significantly more likely than patients in the triple therapy group to satisfy all persistence criteria in definition 1 (risk difference [RD] 13.1% [95% confidence interval (95% CI) 9.2-17.0]), definition 2 (RD 6.4% [95% CI 2.3-10.5]), and definition 3 (RD 9.5% [95% CI 5.5-13.6]). Patients in the TNFi + MTX group also exhibited higher adherence during the first year (RD 7.2% [95% CI 3.8-10.5]).

Conclusion: US Veterans with RA were significantly more likely to be persistent and adherent to combination therapy with TNFi + MTX than triple therapy with nonbiologic DMARDs.

Citing Articles

Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study.

Huang Y, Agarwal S, Chatterjee S, Chen H, Johnson M, Aparasu R Clin Rheumatol. 2023; 43(1):103-116.

PMID: 37540382 DOI: 10.1007/s10067-023-06709-2.

Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis.

Huang Y, Chatterjee S, Agarwal S, Chen H, Johnson M, Aparasu R Explor Res Clin Soc Pharm. 2023; 11:100296.

PMID: 37521021 PMC: 10372178. DOI: 10.1016/j.rcsop.2023.100296.

Trends in Fracture Rates Over Two Decades Among Veterans With Ankylosing Spondylitis.

Merjanah S, Liew J, Bihn J, Fillmore N, Brophy M, Do N Arthritis Care Res (Hoboken). 2023; 75(12):2481-2488.

PMID: 37308459 PMC: 10704387. DOI: 10.1002/acr.25166.

High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis.

Moon D, Kim A, Song B, Kim Y, Kim G, Ahn E Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986479 PMC: 10055887. DOI: 10.3390/ph16030379.

A novel anti-TNF-α drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis.

Oyama S, Ebina K, Etani Y, Hirao M, Kyuuma M, Fujii Y Sci Rep. 2022; 12(1):18102.

PMID: 36302840 PMC: 9613905. DOI: 10.1038/s41598-022-23152-6.

References

Contreras-Yanez I, Ponce de Leon S, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V . Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci. 2010; 340(4):282-90. DOI: 10.1097/MAJ.0b013e3181e8bcb0. View

Hetland M, Christensen I, Tarp U, Dreyer L, Hansen A, Hansen I . Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide.... Arthritis Rheum. 2009; 62(1):22-32. DOI: 10.1002/art.27227. View

Nelson S, Lu C, Teng C, Leng J, Cannon G, He T . The use of natural language processing of infusion notes to identify outpatient infusions. Pharmacoepidemiol Drug Saf. 2014; 24(1):86-92. DOI: 10.1002/pds.3720. View

van Vollenhoven R, Ernestam S, Geborek P, Petersson I, Coster L, Waltbrand E . Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009; 374(9688):459-66. DOI: 10.1016/S0140-6736(09)60944-2. View

Maynard C, Chapko M . Data resources in the Department of Veterans Affairs. Diabetes Care. 2004; 27 Suppl 2:B22-6. DOI: 10.2337/diacare.27.suppl_2.b22. View

Mellins C, Havens J, McDonnell C, Lichtenstein C, Uldall K, Chesney M . Adherence to antiretroviral medications and medical care in HIV-infected adults diagnosed with mental and substance abuse disorders. AIDS Care. 2009; 21(2):168-77. PMC: 5584780. DOI: 10.1080/09540120802001705. View

Ellis J, Erickson S, Stevenson J, Bernstein S, Stiles R, Fendrick A . Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004; 19(6):638-45. PMC: 1492382. DOI: 10.1111/j.1525-1497.2004.30516.x. View

ODell J, Mikuls T, Taylor T, Ahluwalia V, Brophy M, Warren S . Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013; 369(4):307-18. DOI: 10.1056/NEJMoa1303006. View

Contreras-Yanez I, Cabiedes J, Villa A, Rull-Gabayet M, Pascual-Ramos V . Persistence on therapy is a major determinant of patient-, physician- and laboratory- reported outcomes in recent-onset rheumatoid arthritis patients. Clin Exp Rheumatol. 2010; 28(5):748-51. View

10.

Hess L, Raebel M, Conner D, Malone D . Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006; 40(7-8):1280-88. DOI: 10.1345/aph.1H018. View

11.

Markenson J, Gibofsky A, Palmer W, Keystone E, Schiff M, Feng J . Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol. 2011; 38(7):1273-81. DOI: 10.3899/jrheum.101142. View

12.

Perkins D . Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2003; 63(12):1121-8. DOI: 10.4088/jcp.v63n1206. View

13.

Waimann C, Marengo M, de Achaval S, Cox V, Garcia-Gonzalez A, Reveille J . Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence. Arthritis Rheum. 2013; 65(6):1421-9. PMC: 3691007. DOI: 10.1002/art.37917. View

14.

Sewitch M, Abrahamowicz M, Barkun A, Bitton A, Wild G, Cohen A . Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003; 98(7):1535-44. DOI: 10.1111/j.1572-0241.2003.07522.x. View

15.

Saag K, Teng G, Patkar N, Anuntiyo J, Finney C, Curtis J . American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59(6):762-84. DOI: 10.1002/art.23721. View

16.

Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P . Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol. 2012; 39(6):1179-84. DOI: 10.3899/jrheum.111125. View

17.

Bonafede M, Johnson B, Tang D, Shah N, Harrison D, Collier D . Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2015; 67(12):1656-63. PMC: 5063099. DOI: 10.1002/acr.22638. View

18.

Smolen J, Landewe R, Breedveld F, Dougados M, Emery P, Gaujoux-Viala C . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010; 69(6):964-75. PMC: 2935329. DOI: 10.1136/ard.2009.126532. View

19.

Osterberg L, Blaschke T . Adherence to medication. N Engl J Med. 2005; 353(5):487-97. DOI: 10.1056/NEJMra050100. View

20.

Ammassari A, Trotta M, Murri R, Castelli F, Narciso P, Noto P . Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2003; 31 Suppl 3:S123-7. DOI: 10.1097/00126334-200212153-00007. View